Trifluridine-tipiracil

Phase 3Small molecule

Merck & Co.

Trifluridine-tipiracil is one of 176 small molecule programs targeting Intestinal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Solid TumorActive, not recruiting

Advanced Microsatellite Stable Colorectal CancerRecruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Solid TumorPreclinical

Active, not recruiting

Advanced Microsatellite Stable Colorectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Trifluridine-tipiracil

Merck & Co.

Phase 3

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Andriol

AAuxilium

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Vascepa

AAmarin Pharma Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Solid Tumor

NCT04626635

Q2 2027

Phase 3Active, not recruiting

Esophageal Adenocarcinoma

NCT06356311

Q2 2028

Phase 1/2Recruiting

Pembrolizumab

NCT05083481

Q4 2028

Phase 2Recruiting

Advanced Microsatellite Stable Colorectal Cancer

NCT07527858

Phase 1/2Recruiting

Intestinal Cancer

NCT07280377

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT05468892·68 enrolled

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT06887218·57 enrolled

Esophageal Adenocarcinoma1 trial

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06356311·450 enrolled

Pembrolizumab1 trial

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Recruiting· Astellas logo

Astellas·Phase 1/2·NCT05083481·366 enrolled

Intestinal Cancer1 trial

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Recruiting·OOncolytics Biotech·Phase 1/2·NCT07280377·122 enrolled

Colorectal Cancer1 trial

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Suspended·MM.D. Anderson Cancer Center·Phase 2·NCT07011550·7 enrolled

2 more indications

Solid Tumor1 trial

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Active, not recruiting· Regeneron logo

Regeneron·Preclinical·NCT04626635·548 enrolled

Advanced Microsatellite Stable Colorectal Cancer1 trial

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Recruiting· Gilead logo

Gilead·Phase 2·NCT07527858·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Trifluridine-tipiracil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trifluridine-tipiracil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trifluridine-tipiracil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Trifluridine-tipiracil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Esophageal Adenocarcinoma1 trial

Pembrolizumab1 trial

Intestinal Cancer1 trial

Colorectal Cancer1 trial

Solid Tumor1 trial

Advanced Microsatellite Stable Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News